CAMBRIDGE, MASS, November 10, 2022 —Clinicogenomic and lab software company Ovation is pleased to announce today that Marty Miller has been appointed as the company’s Chief Revenue Officer with Hana Dembe appointed to lead Product Marketing. In this role, Miller will drive growth of the Data and Lab Information Management System (LIMS) businesses with oversight over sales, marketing and strategic partnerships efforts while Hana will lead product go to market and commercialization efforts in conjunction with Marty.
“Marty and Hana both have a deep understanding of the life sciences data industry and exceptional experience as team leaders,” said Curt Medeiros, CEO of Ovation. “I am confident that their commercial and go to market expertise as well as their strong relationships with industry leaders will help Ovation achieve our mission of advancing precision medicine by enabling high impact uses of clinicogenomic data in drug development.”
Marty brings to Ovation a wealth of expertise in building high performance sales teams and launching of new products across multiple healthcare markets, specifically in the real world data and analytics space. Most recently Marty was the Chief Growth Officer for Life Sciences, Provider Analytics and State Government at Optum. Hana complements this background with her expertise in product marketing and go to market strategy for data products, most recently leading Product Marketing for the Evidence business at Flatiron Health.
“I’m honored to be joining such a talented team of mission driven individuals who are committed to improving the way that genomics are used in drug research and development,” said Miller. “Leading Ovation, a cutting edge company that captures biobanked data for use in omics sequencing, surveillance tracking and viromics, is a once in a lifetime opportunity to be at the forefront of genomics innovation that could truly change lives.”
Today’s appointments are the latest strategic leadership enhancements being made to accelerate the next phase of growth in life sciences for the company. The new commercial structure will enable expanded engagement with life sciences companies as the company builds capacity across its genomic data, LIMS and research network products.
In recent months, Ovation has achieved significant growth in its genomic data and biobanking products, focusing specifically on endocrine, infectious disease and auto-immune disorders. Ovation has over 1.3 million geographically and demographically diverse, consented biospecimens from over 542,000 unique patients.
Ovation is a clinicogenomic data company committed to accelerating the development of precision medicine. Ovation provides life sciences with access to high-quality, consented, and representative genomic data linked to a variety of rich, longitudinal phenotypic data at scale. Ovation’s data enable life sciences researchers to advance biomarker development and validation, target identification and resistance mechanism of action within new populations. A diverse network of clinical laboratories use Ovation’s cloud-based LIMS to quickly adopt innovative molecular tests while biobanking and transforming remnant samples into comprehensive research grade data across disease areas. For more information, visit www.ovation.io.